texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Sharon T. Wilks, M.D., FACP

General Summary

Dr. Sharon T. Wilks is board certified in medical oncology, hematology and internal medicine. Dr. Wilks’ career began in the US Air Force where she received her medical education, remained in medical service for 12 years and received two medals of commendation. While in the military, Dr. Wilks was successful in bringing the first breast cancer prevention clinical trial to Wilford Hall Medical Center in 1995, was appointed as the physician to head the breast cancer prevention program and received two Department of Defense Grants to develop early screening programs that included providing free mammograms to over 800 women. Following service in the military, she continued her educational efforts and community advocacy in addition to maintaining a busy oncology practice.

Dr. Wilks has worked to foster a collaboration between several San Antonio breast cancer organizations, to bring these groups together to better meet community needs and work toward a common goal. She founded and now chairs an organization that involves the Cancer Therapy and Research Center (CTRC), the Alamo Breast Cancer Foundation, the American Cancer Society (ACS), WINGS, the Susan G. Komen Foundation and the University of Texas Nursing School, and provides the annual "Breast Cancer Update" every October for the public and healthcare providers.

In addition, Dr. Wilks founded the Alamo Breast Cancer Council in 2005 to secure grant monies to fill a need that she had identified, and was awarded a sizable grant from the Baptist Healthcare Foundation to produce a patient-friendly booklet providing concise information for newly-diagnosed breast cancer patients regarding available treatment options, and to give patients decision-making tools in their journey through seeing specialists and beginning their treatment. Over 10,000 English copies and over 5000 copies in Spanish have been distributed so far. In 2006, Dr. Wilks changed the name to the Alamo Cancer Council (ACC) after seeing the need to provide the same type of information to patients with colon cancer, and wrote a similar booklet for these patients. Both booklets fill the large information gap that all patients feel between the time they receive their diagnosis and the time they see their first specialist. Due to the success of the ACC, the organization has been officially recognized by the Texas Cancer Council.

Dr. Wilks has taken leadership roles in numerous other community organizations including, serving as the Chairman of the Cancer Committee for Baptist Healthcare System, working as a mentor for the Alamo Breast Cancer Foundation, sitting on the board of directors and the grants committee of the local Susan G. Komen Foundation and is an active speaker for both the ACS and the Alamo Breast Cancer Foundation. She is currently a reviewer for the Texas State Board of Medical Examiners and an investigator for the National Cancer Institute.

Education

  • Fellowship
    Medical Oncology, Lackland AFB, San antonio, TX
  • Residency
    Internal Medicine, Lackland AFB, San Antonio, TX
  • Internship
    Internal Medicine, Lackland AFB, San Antonio, TX
  • Medical Doctorate
    Uniformed Services University of Health Sciences, Bethesda, MD

Medical Practice

Other Information

In her spare time, Dr. Wilks enjoys reading, walking, shopping and travel. Her husband is a private practice cardiologist and they have three children, two girls and a boy.

Accolades & Memberships

Dr. Wilks has the honor of being selected to "Texas Super Doctors" published in Texas Monthly magazine in 2010 and 2011.

Community Service

Research Interest

Publications

  • APF530 (Granisetron Inj Extended-Release) in a Three-Drug Regimen for Delayed CINV in Highly Emetogenic Chemotherapy

    Future Oncology, 2016

  • Molecular Alterations and Everolimus  Efficacy in HER2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Analysis from BOLERO-1 and BOLERO-3.

    Journal of Clinical Oncology, 2015

  • Phase I study of GR antagonist Mifepristone (M) in combination with Eribulin (E)in advanced solid tumors, with dose expansion in patients (pts)with GR-positive Triple Negative Breast Cancer (TNBC).

    San Antonio Breast Cancer Symposium, 2015

  • Case Studies in the Management of Metastatic Breast Cancer with Eribulin.

    Clinical Medicine Insights: Oncology, 2015

  • Impact of Prior Anthracycline or Taxane on Eribulin Effectiveness as First-Line Treatment for Metastatic Breast Cancer: Results from Two Phase 2, Multicenter, Single-arm Studies.

    Springer Plus Open Journal Volume 4, 2015

Show all Publications
  • Phase 3 Comparison of APF530 versus Ondansetron, Each in a Guideline-Recommended 3-drug Regimen for Prevention of Chemotherapy Induced Nausea and Vomiting due to Anthracycline+ Cyclophosphamide (AC) Based Highly Emetogenic Chemotherapy (HEC) Regime.

    San Antonio Breast Cancer Symposium, 2015

  • Potential of Overcoming Resistance to HER2-Targeted Therapies through the PI3K/Akt/mTOR pathway.

    The Breast, 2015

  • Weekly nab-Paclitaxel plus Gemcitabine (Gem) or Carboplatin (Carbo) versus Gem/Carbo as First Line Treatment for Metastatic Triple Negative (mTNBC) in a Phase II/III Trial (TnAcity).

    American Society of Clinical Oncology, 2015

  • Predictive Biomarkers of Everolimus efficacy in HER2+ Advanced Breast Cancer: Combined Exploratory Analysis from BOLERO-1 and BOLERO-3.

    American Society of Clinical Oncology, 2015

  • Everolimus for Women with Trastuzumab Resistant, HER2 Positive, Advanced Breast Cancer (BOLERO-3): A Randomized, Double Blind, Placebo Controlled Phase III Trial.

    The Lancet Oncology, 2014

  • Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate + Trastuzumab as First Line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer.

    Clinical Breast Cancer, 2014

  • Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate + Trastuzumab as First Line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer.

    San Antonio Breast Cancer Symposium, 2013

  • Eribulin Mesylate with Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2)-Positive Breast Cancer: Preliminary Results from a Phase 2, Multicenter, Single-Arm Study

    35th Annual San Antonio Breast Cancer Symposium, 2012